Biotech Values

[dewophile]

? One of the arms was ifn-alpha and the ifn-L arms were comparable, but not really better from an efficacy standpoint

sorry i was careless and missed that, but unless i am looking at different data the lambda arms did much much better in the difficult to treat genotypes (particularly on the week 4 metric which is most closely associated with attaining SVR)
the data in fact is not quite as good as telaprevir, but not far off. whether there will be an incremental efficacy benefit if yo uadd T to the regimen is not clear, but i bet there will be a small but real benefit (in addition to better tolerability) - and it stands to reason a ph 3 will be head to head with T in both arms